Downey Amanda E, Chaphekar Anita V, Woolley Joshua, Raymond-Flesch Marissa
Department of Pediatrics, University of California, San Francisco, CA, USA.
Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA, USA.
J Eat Disord. 2024 Apr 24;12(1):49. doi: 10.1186/s40337-024-01005-z.
Clinical trials using psilocybin therapy to treat anorexia nervosa (AN) are currently underway. The safety and tolerability of psilocybin is of utmost importance in individuals with AN who may present unique medical vulnerabilities. The purpose of this review is to describe how the common physiologic adverse effects of psilocybin may impact medical complications experienced by individuals with AN in clinical trials of psilocybin therapy.
The physiologic underpinnings of common adverse effects following psilocybin administration are described, including tachycardia, hypertension, electrocardiogram changes, nausea, headache, and lightheadedness. These anticipated physiologic changes are described in relation to the common medical correlates seen in individuals with AN. Risk mitigation strategies for each adverse effect are proposed.
Early evidence suggests that psilocybin therapy is well-tolerated in individuals with AN. Understanding the unique medical complications of AN, and how they may be impacted by common physiologic adverse effects of psilocybin administration, leads to tailored risk mitigation strategies to enhance safety and tolerability of this novel intervention.
目前正在进行使用裸盖菇素疗法治疗神经性厌食症(AN)的临床试验。在可能存在独特医学脆弱性的神经性厌食症患者中,裸盖菇素的安全性和耐受性至关重要。本综述的目的是描述裸盖菇素常见的生理不良反应如何在裸盖菇素疗法的临床试验中影响神经性厌食症患者所经历的医学并发症。
描述了服用裸盖菇素后常见不良反应的生理基础,包括心动过速、高血压、心电图变化、恶心、头痛和头晕。这些预期的生理变化与神经性厌食症患者中常见的医学相关情况相关。针对每种不良反应提出了风险缓解策略。
早期证据表明,神经性厌食症患者对裸盖菇素疗法耐受性良好。了解神经性厌食症独特的医学并发症,以及它们如何受到服用裸盖菇素常见生理不良反应的影响,有助于制定针对性的风险缓解策略,以提高这种新型干预措施的安全性和耐受性。